Trial Profile
Comparative efficacy and safety of saxagliptin combination therapy with acarbose, or gliclazide modified release (MR), or metformin therapy in drug naive patients with type 2 diabetes mellitus (T2DM )
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Dec 2022
Price :
$35
*
At a glance
- Drugs Saxagliptin (Primary) ; Acarbose; Gliclazide; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 27 Apr 2016 New trial record